96. クローン病
[臨床試験数:2,209,薬物数:1,276(DrugBank:240),標的遺伝子数:166,標的パスウェイ数:210

Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-001295-65-IT
(EUCTR)
01/12/201427/11/2014Phase II study evaluating Ovasave, a cell therapy, in patient with active Crohn's DiseaseA phase IIb, multicentre, randomised, double-blinded (DB), placebo-controlled, multi-dose and multi-injection, parallel groups study to evaluate the efficacy and the safety of Ovasave (ovalbumin-specific autologous Treg cells (ova-Treg)) in patients with active refractory Crohn’s Disease (Crohn’s And Treg Study: CATS29) - CATS29 Moderately to severely active Crohn's Disease
MedDRA version: 17.1;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Ovasave
INN or Proposed INN: Ova-Treg
Other descriptive name: Autologous ovalbumin-specific type 1 regulatory T lymphocytes expanded population
Product Name: Ovasave
INN or Proposed INN: Ova-Treg
Other descriptive name: Autologous ovalbumin-specific type 1 regulatory T lymphocytes expanded population
Product Name: Ovasave
INN or Proposed INN: Ova-Treg
Other descriptive name: Autologous ovalbumin-specific type 1 regulatory T lymphocytes expanded population
TxCellNULLNot RecruitingFemale: yes
Male: yes
200Phase 2Belgium;Austria;Germany;Italy
2EUCTR2014-001295-65-AT
(EUCTR)
01/12/201419/11/2014Phase II study evaluating Ovasave, a cell therapy, in patient with active Crohn's DiseaseA phase IIb, multicentre, randomised, double-blinded (DB), placebo-controlled, single-dose and multi-injection, parallel groups study to evaluate the efficacy and the safety of Ovasave (ovalbumin-specific autologous Treg cells (ova-Treg)) in patients with active refractory Crohn’s Disease (Crohn’s And Treg Study: CATS29) - CATS29 Moderately to severely active Crohn's Disease
MedDRA version: 18.1;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Ovasave
INN or Proposed INN: Ova-Treg
Other descriptive name: Autologous ovalbumin-specific type 1 regulatory T lymphocytes expanded population
TxCellNULLNot RecruitingFemale: yes
Male: yes
170Phase 2Belgium;Austria;Germany;Italy
3NCT02327221
(ClinicalTrials.gov)
December 201423/12/2014Study Evaluating Ovasave, an Autologous Cell Therapy, in Patients With Active Crohn's DiseaseA Phase IIb, Multicentre, Randomised, Double-blinded, Placebo-controlled, Multi-dose and Multi-injection, Parallel Groups Study to Evaluate the Efficacy and the Safety of Ovasave in Patients With Active Refractory Crohn's DiseaseCrohn DiseaseDrug: Ovasave;Drug: PlaceboTxCellNULLTerminated18 Years70 YearsAll32Phase 2Austria;Belgium;France;Germany;Italy;United Kingdom
4EUCTR2014-001295-65-BE
(EUCTR)
28/11/201417/11/2014Phase II study evaluating Ovasave, a cell therapy, in patient with active Crohn's DiseaseA phase IIb, multicentre, randomised, double-blinded (DB), placebo-controlled, single-dose and parallel-group study to evaluate the efficacy and the safety of Ovasave (ovalbumin-specific autologous Treg cells (Ova-Treg)) in patients with active refractory Crohn's Disease (Crohn's And Treg Study: CATS29) - CATS29 Moderately to severely active Crohn's Disease
MedDRA version: 19.0;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Ovasave
INN or Proposed INN: Ova-Treg
Other descriptive name: Autologous ovalbumin-specific type 1 regulatory T lymphocytes expanded population
TxCellNULLNot RecruitingFemale: yes
Male: yes
117Phase 2Belgium;Austria;Germany;Italy
5EUCTR2014-001295-65-DE
(EUCTR)
25/11/201419/11/2014Phase II study evaluating Ovasave, a cell therapy, in patient with active Crohn's DiseaseA phase IIb, multicentre, randomised, double-blinded (DB), placebo-controlled, single-dose and multi-injection, parallel groups study to evaluate the efficacy and the safety of Ovasave (ovalbumin-specific autologous Treg cells (ova-Treg)) in patients with active refractory Crohn’s Disease (Crohn’s And Treg Study: CATS29) - CATS29 Moderately to severely active Crohn's Disease
MedDRA version: 18.1;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Ovasave
INN or Proposed INN: Ova-Treg
Other descriptive name: Autologous ovalbumin-specific type 1 regulatory T lymphocytes expanded population
TxCellNULLNot RecruitingFemale: yes
Male: yes
170Phase 2Belgium;Austria;Germany;Italy